Novartis CEO Calls Potential Schering-Plough Merger “Very Interesting”

A Novartis/Schering-Plough merger would increase Novartis' OTC portfolio by about 57% to $2.77 bil. and give the Swiss firm control over the formidable Claritin allergy and hives relief franchise